TrajSurv-mPC: Learning From Prostate-Specific Antigen Trajectories for Interpretable and Generalizable Survival Prediction in Metastatic Prostate Cancer.

Authors

Sihang Zeng, Lukas Owens, Lucas J Liu, Sigrid Carlsson, Jonathan S Fainberg, Vincent P Laudone, Martin W Schoen, Isla P Garraway, Ruth Etzioni

Published in

JCO clinical cancer informatics. Volume 10. Issue 3. Pages e2500328. Epub Sep 29, 2026.

Abstract

Conventional prognostic models for metastatic prostate cancer (mPC) typically rely on summary features like prostate-specific antigen (PSA) doubling time, often obscuring informative longitudinal dynamics. We developed TrajSurv-mPC, a flexible deep learning framework that analyzes full premetastasis patient trajectories-including serial PSA and treatments-to improve postmetastasis overall survival (OS) prediction.
The TrajSurv-mPC framework was developed and evaluated using two independent cohorts: Memorial Sloan Kettering (MSK; n = 403) and Veterans Affairs (VA; n = 9,984). To demonstrate its architectural robustness, the framework's sequential modeling was implemented with both Long Short-Term Memory (LSTM) and Transformer backbones. The models used baseline characteristics alongside longitudinal PSA and treatment data to predict OS from the time of metastasis detection. Performance was compared against models using summary features. Generalizability was assessed via external validation (training on a harmonized VA subcohort; testing on MSK). Interpretability was explored through post hoc hidden state clustering, a simulation study, and a case study.
Compared with summary-feature models (C-indices: 0.650-0.677 internally; 0.635-0.651 externally), the TrajSurv-mPC framework achieved C-indices of 0.723-0.747 (MSK) and 0.711-0.754 (VA) in internal validations, and 0.693 (LSTM, P = .02) and 0.708 (Transformer, P = .008) in cross-cohort external validations across both architectures. Clustering stratified distinct prognostic groups (P < .001). Furthermore, simulation and case studies showed that predicted risk varied in clinically plausible directions across different treatment response trajectories.
By modeling the complete premetastasis PSA trajectory, the TrajSurv-mPC framework improves prognostic risk prediction in mPC. Its robust performance across different sequential backbones demonstrates the generalizable added value of dynamic patterns in distinct populations. Combining this framework with complementary measures based on imaging or genomics may enhance personalization of mPC management.

PMID:
42809793
Bibliographic data and abstract were imported from PubMed on 30 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.